deferiprone has been researched along with Diabetes Mellitus in 7 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferasirox is an oral chelator." | 5.46 | Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. ( Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017) |
| " We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with beta-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications." | 5.12 | Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. ( Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH, 2006) |
| "In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39." | 3.83 | Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016) |
| "Diabetes mellitus is a common endocrinopathy in patients with β-thalassaemia major (β-TM), which is high prevalent in southern China." | 1.46 | Prevalence of diabetes mellitus in Chinese children with thalassaemia major. ( Bajoria, R; Chatterjee, R; Jiang, Y; Lai, Y; Liang, Y; Pan, H; Su, H; Xia, N, 2017) |
| "Deferasirox is an oral chelator." | 1.46 | Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. ( Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, Y | 1 |
| Bajoria, R | 1 |
| Jiang, Y | 1 |
| Su, H | 1 |
| Pan, H | 1 |
| Xia, N | 1 |
| Chatterjee, R | 1 |
| Lai, Y | 1 |
| Poggi, M | 1 |
| Sorrentino, F | 1 |
| Pugliese, P | 1 |
| Smacchia, MP | 1 |
| Daniele, C | 1 |
| Equitani, F | 1 |
| Terlizzi, F | 1 |
| Guitarrini, MR | 1 |
| Monti, S | 1 |
| Maffei, L | 1 |
| Losardo, A | 1 |
| Pasin, M | 1 |
| Toscano, V | 1 |
| Karimi, M | 1 |
| Avazpour, A | 1 |
| Haghpanah, S | 1 |
| Toosi, F | 1 |
| Badie, A | 1 |
| Platis, O | 1 |
| Anagnostopoulos, G | 1 |
| Farmaki, K | 1 |
| Posantzis, M | 1 |
| Gotsis, E | 1 |
| Tolis, G | 1 |
| Wang, CH | 1 |
| Wu, KH | 1 |
| Tsai, FJ | 1 |
| Peng, CT | 1 |
| Tsai, CH | 1 |
| Kidson-Gerber, GL | 1 |
| Francis, S | 1 |
| Lindeman, R | 1 |
| al-Refaie, FN | 1 |
| Wonke, B | 1 |
| Wickens, DG | 1 |
| Aydinok, Y | 1 |
| Fielding, A | 1 |
| Hoffbrand, AV | 1 |
2 trials available for deferiprone and Diabetes Mellitus
| Article | Year |
|---|---|
Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Thera | 2004 |
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modali | 2006 |
5 other studies available for deferiprone and Diabetes Mellitus
| Article | Year |
|---|---|
Prevalence of diabetes mellitus in Chinese children with thalassaemia major.
Topics: Alanine Transaminase; beta-Thalassemia; Blood Glucose; Child; China; Deferiprone; Diabetes Mellitus; | 2017 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe | 2016 |
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; De | 2017 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug | 2008 |
Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
Topics: Adolescent; Adult; Blood Glucose; Deferiprone; Deferoxamine; Diabetes Mellitus; Female; Glucose Tole | 1994 |